Table 3.
Sensitivity analyses
| Osteoporosis/n | Prevalence/% | Adjusted OR (95% CI)a | |
|---|---|---|---|
| Sensitivity analyses 1b | |||
| CDAI (continuous) | 415/6716 | 6.7 | 0.97 (0.96-0.99) |
| CDAI categories | |||
| Quantile 1 | 132/1544 | 8.5 | 1.00 (Ref.) |
| Quantile 2 | 113/1544 | 7.3 | 0.90 (0.65-1.25) |
| Quantile 3 | 96/1544 | 6.2 | 0.71 (0.49-1.04) |
| Quantile 4 | 74/1544 | 4.8 | 0.57 (0.35-0.92) |
| Sensitivity analyses 2c | |||
| CDAI (continuous) | 830/10554 | 7.9 | 0.96 (0.95-0.98) |
| CDAI categories | |||
| Quantile 1 | 281/2636 | 10.7 | 1.00 (Ref.) |
| Quantile 2 | 225/2636 | 8.5 | 0.84 (0.66-1.06) |
| Quantile 3 | 181/2636 | 6.9 | 0.80 (0.61-1.05) |
| Quantile 4 | 143/2636 | 5.4 | 0.66 (0.47-0.94) |
| Sensitivity analyses 3d | |||
| DAQ (continuous) | |||
| DAQ categories | 915/10989 | 8.3 | 0.90 (0.84-0.95) |
| <5 | 355/4241 | 8.4 | 1.00 (Ref.) |
| ≥5 | 560/6748 | 8.3 | 0.79 (0.65-0.97) |
All models are adjusted for age, sex, race/ethnicity, family income, BMI, eGFR, calorie intake, physical activity and drinking status;
Excluding participants taking medicines that may affect BMD which include thiazide diuretics, glucocorticoids, bisphosphonates, allopurinol, sex hormone therapy, thyroid replacement therapy, bone resorption inhibitors and excluding participants with chronic kidney disease, diabetes, and rheumatoid arthritis;
Calculating CDAI based on the averages of two NHANES dietary recall;
Accessing dietary antioxidant capacity by using DAQ score.
CDAI: Composite Dietary Antioxidant Index; DAQ: Dietary Antioxidant Quality; BMI: Body Mass Index; eGFR: estimated Glomerular Filtration Rate; BMD: Bone Mass Density; NHANE: National Health and Nutrition Examination Survey.